We ran a compassionate use nationwide programme (ABACUS) to provide access to ombitasvir, paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for hepatitis C virus (HCV) genotype 1 infection and ombitasvir, paritaprevir, and ritonavir, plus ribavirin for HCV genotype 4 infection in patients with cirrhosis at high risk of decompensation while approval of these regimens was pending in Italy.
Petta, S., Marzioni, M., Russo, P., Aghemo, A., Alberti, A., Ascione, A., et al. (2017). Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. THE LANCET. GASTROENTEROLOGY & HEPATOLOGY, 2(6), 427-434 [10.1016/S2468-1253(17)30048-1].
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study
BRUNO, SALVATORE;MESSINA, VALERIA;PERNO, CARLO FEDERICO;RENDINA, LUCIANO MARIA;ANDREONI, MASSIMO;TETI, ELISABETTA;ANGELICO, MARIO;PERSICO, MARIA;SOLINAS, ALICE;IZZI, ALESSANDRO;MONTI, MARCO;BARONE, MICHELE;DI LEO, ANDREA;CRISTAUDO, ALESSANDRO;VULLO, VINCENZO;RIZZO, STEFANIA;
2017-01-01
Abstract
We ran a compassionate use nationwide programme (ABACUS) to provide access to ombitasvir, paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for hepatitis C virus (HCV) genotype 1 infection and ombitasvir, paritaprevir, and ritonavir, plus ribavirin for HCV genotype 4 infection in patients with cirrhosis at high risk of decompensation while approval of these regimens was pending in Italy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.